Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945
May 27, 2021 07:00 ET
|
Pulmocide
Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945 London, UK, 27 May 2021 – Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company...
Jeito Capital leads oversubscribed $92 million Series C financing round in Pulmocide
May 27, 2021 02:00 ET
|
Jeito Capital
Jeito Capital leads oversubscribed $92 million Series C financing round in Pulmocide Jeito selects Pulmocide as its fourth investment since launching the fundPulmocide is a late-stage biopharma...
Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945
May 27, 2021 02:00 ET
|
Pulmocide
Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945 London, UK, 27 May 2021 – Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company...
Pulmocide announces publication of clinical data in two peer-reviewed publications highlighting potential of PC945, a novel inhaled antifungal drug candidate, in lung infections
March 11, 2021 08:00 ET
|
Pulmocide
Pulmocide announces publication of clinical data in two peer-reviewed publications highlighting potential of PC945, a novel inhaled antifungal drug candidate, in lung infections Case studies...
Pulmocide announces Journal of Antimicrobial Chemotherapy publication of novel antifungal PC945 activity against Candida auris, a health threat gaining global prominence
August 13, 2019 07:00 ET
|
Pulmocide
Pulmocide announces Journal of Antimicrobial Chemotherapy publication of novel antifungal PC945 activity against Candida auris, a health threat gaining global prominence C.auris is often multi-drug...
Pulmocide announces Scientific Reports (Nature Research) publication showing PC945 in combination with standard antifungal treatment causes a synergistic effect against Aspergillus fumigatus
July 02, 2019 07:00 ET
|
Pulmocide
Pulmocide announces Scientific Reports (Nature Research) publication showing PC945 in combination with standard antifungal treatment causes a synergistic effect against Aspergillus fumigatus ...
Pulmocide presents clinical update from promising antifungal program at 2019 Respiratory Innovation Summit
May 17, 2019 07:00 ET
|
Pulmocide
Pulmocide presents clinical update from promising antifungal program at 2019 Respiratory Innovation Summit London, UK; 17 May 2019 – Pulmocide Ltd, which is developing first-in-class inhaled...